We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    edasalonexent | DMD
Previous Study | Return to List | Next Study

Phase 1/2 Study in Boys With Duchenne Muscular Dystrophy (MoveDMD®)

This study is ongoing, but not recruiting participants.
ClinicalTrials.gov Identifier:
First Posted: May 8, 2015
Last Update Posted: May 1, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Catabasis Pharmaceuticals

The MoveDMD study is a 3-part, Phase 1/2, multi-site study to evaluate the safety, efficacy, pharmacokinetics (PK) and pharmacodynamics (PD) of edasalonexent (also known as CAT-1004) in pediatric patients with a genetically confirmed diagnosis of DMD. Male patients from ≥4 to <8 years of age will be enrolled.

Edasalonexent is an orally administered small molecule targeted to inhibit activated NF-κB, a molecule that is activated from infancy in DMD and which is central to causing muscle damage and preventing muscle regeneration. Data on magnetic resonance imaging of the lower and upper leg muscles, physical function (including timed function tests) and muscle strength will be studied.

Condition Intervention Phase
Muscular Dystrophy, Duchenne Drug: Edasalonexent Drug: Placebo Phase 1 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1/2 Study of Edasalonexent (CAT-1004) in Pediatric Patients With Duchenne Muscular Dystrophy

Resource links provided by NLM:

Further study details as provided by Catabasis Pharmaceuticals:

Primary Outcome Measures:
  • Safety and tolerability (Adverse Events) [ Time Frame: 12 Weeks ]
  • Muscle composition and inflammation as measured by MRI [ Time Frame: 12 Weeks ]

Secondary Outcome Measures:
  • Physical function, muscle strength, and parent/proxy reported physical functioning/quality of life [ Time Frame: 12 Weeks ]
  • Edasalonexent PK and PD measures [ Time Frame: 12 Weeks ]

Enrollment: 31
Study Start Date: April 2016
Estimated Study Completion Date: March 2018
Primary Completion Date: January 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cohort B1
Edasalonexent 67 mg/kg/day
Drug: Edasalonexent
67 mg/kg/day
Other Name: CAT-1004
Experimental: Cohort B2
Edasalonexent 100 mg/kg/day
Drug: Edasalonexent
100 mg/kg/day
Other Name: CAT-1004
Placebo Comparator: Cohort B3 Drug: Placebo

Detailed Description:

Part A is now complete. All three doses of edasalonexent tested were generally well tolerated with no safety signals observed. The majority of adverse events were mild, and the most common adverse events were gastrointestinal (primarily diarrhea). There were no serious adverse events and no drug discontinuations.

Part B was a randomized, double-blind, placebo-controlled, multiple dose study to evaluate the safety, efficacy, PK, and PD of edasalonexent over 12 weeks. Patients who participated in Part A also participated in Part B, along with newly enrolled patients. Patients received either edasalonexent 67 mg/kg/day, edasalonexent 100 mg/kg/day, or placebo in Part B. Part B is now complete and safety signals were not observed in either treatment group.

Following completion of Part B, patients receive edasalonexent for 60 weeks in Part C, the open-label portion of the MoveDMD study. Based on the results from Part B of the study, patients on the 67 mg/kg/day treatment will be switched to the 100 mg/kg/day treatment for the remainder of Part C. Patients on the 100 mg/kg/day treatment will remain on the 100 mg/kg/day treatment for the remainder of Part C.


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   4 Years to 7 Years   (Child)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Written informed consent from parent or legal guardian prior to participation and, for patients who are 7 years of age, written assent from patient
  • Diagnosis of DMD based on a clinical phenotype with increased serum CK and the presence of a mutation in the dystrophin gene known to be associated with a DMD phenotype
  • Ability to walk independently (assistive devices are permitted)
  • Adequate immunization for influenza and varicella

Exclusion Criteria:

  • Use of corticosteroids within prior 6 months of treatment initiation or planning to initiate steroid therapy within the next 6 months
  • Other prior or ongoing significant medical conditions
  • Exposure to another investigational drug (such as eteplirsen or idebenone) within 28 days prior to start of study treatment or ongoing participation in any other therapeutic clinical trial

    • Note: There are separate criteria for patients who participated in Part A versus newly enrolling patients. New patients must meet all of the Part A entry criteria to participate in Part B.

Patients who participated in Part A must meet the following criteria to participate in Part B:

  • Completed Part A
  • Continue to meet all of the Part A entry criteria, including an absence of safety concerns (however, patients may be ≥8 years of age)

There are no entry criteria for Part C; all patients who complete Part B will automatically continue in Part C

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02439216

United States, California
Los Angeles, California, United States, 90095
United States, Florida
Gainesville, Florida, United States, 32610
Orlando, Florida, United States, 32827
United States, Oregon
Portland, Oregon, United States, 97239
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
Catabasis Pharmaceuticals
  More Information

Responsible Party: Catabasis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT02439216     History of Changes
Other Study ID Numbers: CAT-1004-201
First Submitted: April 29, 2015
First Posted: May 8, 2015
Last Update Posted: May 1, 2017
Last Verified: April 2017

Keywords provided by Catabasis Pharmaceuticals:
Muscular Dystrophies
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Duchenne muscular dystrophy

Additional relevant MeSH terms:
Muscular Dystrophies
Muscular Dystrophy, Duchenne
Muscular Disorders, Atrophic
Muscular Diseases
Musculoskeletal Diseases
Neuromuscular Diseases
Nervous System Diseases
Genetic Diseases, Inborn
Genetic Diseases, X-Linked